ovel diagnostic markers to evaluate gut dysbiosis in patients with sepsis
Not Applicable
Recruiting
- Conditions
- Sepsis
- Registration Number
- JPRN-UMIN000048780
- Lead Sponsor
- Chiba University Hospital Emergency and Critical Care Medicine 1-8-1 Inohana, Chuo, Chiba 260-8677, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with inflammatory bowel disease Patients with diarrhea prior to ICU admission Patients who have received multiple antimicrobial agents for a long period of time prior to ICU admission Patients who are judged by the principal investigator to be inappropriate as study subjects
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie gut dysbiosis in sepsis as explored in JPRN-UMIN000048780?
How do novel gut dysbiosis biomarkers from JPRN-UMIN000048780 compare to standard sepsis diagnostic tools?
What specific gut microbiota markers predict sepsis progression in the Chiba University observational study?
Are there potential adverse events associated with gut microbiome-based diagnostics for sepsis?
What combination therapies show promise alongside gut dysbiosis markers for sepsis management?